Detection Of Hepatic Metastases Research Articles

Surveillance for Metastasis in High-Risk Uveal Melanoma Patients: Standard versus Enhanced Protocols.

to evaluate the effectiveness of enhanced surveillance protocols (EP) utilizing high frequency (HF) or enhanced modality (EM) compared to the standard protocol (SP) in detecting metastasis and determining their impact on overall survival (OS) in high-risk uveal melanoma (UM) patients. A total of 87 consecutive patients with Class 2 (high risk) primary UM were enrolled, with negative baseline systemic staging. The patients underwent systemic surveillance with either SP (hepatic ultrasonography [US] every 6 months) or EP (either HF [US every 3 months] or EM [incorporation hepatic computed tomography/magnetic resonance imaging]) following informed discussion. The main outcome measures were largest diameter of largest hepatic metastasis (LDLM), number of hepatic metastatic lesions, time to detection of metastasis (TDM), and OS. This study revealed significant differences in LDLM between surveillance protocols, with the use of EP detecting smaller metastatic lesions (HF, EM, and SP were 1.5 cm, 1.6 cm, and 6.1 cm, respectively). Patients on the EM protocol had a lower 24-month cumulative incidence of >3 cm metastasis (3.5% EM vs. 39% SP; p = 0.021), while those on the HF protocol had a higher 24-month cumulative incidence of ≤3 cm metastasis compared to SP (31% HF vs. 10% SP; p = 0.017). Hazard of death following metastasis was significantly reduced in the EP (HR: 0.25; 95% CI: 0.07, 0.84), HF (HR: 0.23; 95% CI: 0.06, 0.84), and EM (HR: 0.11; 95% CI: 0.02, 0.5) groups compared to SP. However, TDM and OS did not significantly differ between protocols. Enhanced surveillance protocols improved early detection of hepatic metastasis in UM patients but did not translate into a survival advantage in our study cohort. However, early detection of metastasis in patients receiving liver-directed therapies may lead to improved overall survival.

Biliary Carcinoembryonic Antigen (CEA) Levels: The Role in Detection of Occult Hepatic Metastases in Colorectal Carcinoma

Objective: Colorectal carcinoma (CRC) is a major public health concern, often complicated by hepatic metastasis. Despite the widespread use of serum Carcinoembryonic Antigen (CEA) for postoperative monitoring, early detection of hepatic metastasis remains elusive. This study aims to evaluate the prognostic significance of CEA levels in both peripheral blood and gallbladder bile for predicting hepatic metastasis in CRC patients, and to explore its potential utility for personalized treatment regimens. Materials and Methods: A prospective randomized study was conducted over three years, enrolling 31 participants, 21 of whom underwent curative operations for CRC. Preoperative and postoperative CEA levels were assessed with rigorous diagnostic imaging and histological examinations. Patients were stratified into groups based on liver metastasis, postoperative chemotherapy, and CEA levels in both blood and bile. Results: A statistically significant difference was found in biliary CEA levels between patients with (mean = 129.22 ng/ml) and without intraoperative liver metastasis (mean = 33.16 ng/ml), p-value = 0.01. Serum and biliary CEA levels were robustly correlated, p > 0.05. Biliary CEA values differed significantly across Duke's stages, with particular significance between the control group and Duke's stage D (p < 0.001). Among patients without intraoperative liver metastasis but with biliary CEA >10 ng/ml, 80% developed liver metastasis postoperatively despite undergoing chemotherapy. Conclusion: This research highlights the pivotal role of biliary CEA levels in diagnosing latent hepatic metastases in colorectal cancer. Demonstrating superior sensitivity compared to traditional serum tests, biliary CEA presents a potential shift in early detection. Elevated levels suggest expanded therapeutic options, from timely hepatectomies to adopting radiofrequency ablation and anti-CEA monoclonal antibodies, enhancing the likelihood of better patient outcomes. Essentially, these findings enhance our understanding of colorectal cancer, emphasizing the importance of personalized care, early diagnosis, and customized treatments, thereby directing us toward better patient outcomes.

Targeted Training Reduces Search Errors but Not Classification Errors for Hepatic Metastasis Detection at Contrast-Enhanced CT

Methods are needed to improve the detection of hepatic metastases. Errors occur in both lesion detection (search) and decisions of benign versus malignant (classification). Our purpose was to evaluate a training program to reduce search errors and classification errors in the detection of hepatic metastases in contrast-enhanced abdominal computed tomography (CT). After Institutional Review Boardapproval, we conducted a single-group prospective pretest-posttest study. Pretest and posttest were identical and consisted of interpreting 40 contrast-enhanced abdominal CT exams containing 91 liver metastases under eye tracking. Between pretest and posttest, readers completed search training with eye-tracker feedback and coaching to increase interpretation time, use liver windows, and use coronal reformations. They also completed classification training with part-task practice, rating lesions as benign or malignant. The primary outcome was metastases missed due to search errors (<2seconds gaze under eye tracker) and classification errors (>2seconds). Jackknife free-response receiver operator characteristic (JAFROC) analysis was also conducted. A total of 31 radiologist readers (8 abdominal subspecialists, 8 nonabdominal subspecialists, 15 senior residents/fellows) participated. Search errors were reduced (pretest 11%, posttest 8%, difference 3% [95% confidence interval, 0.3%-5.1%], P =.01), but there was no difference in classification errors (difference 0%, P=.97) or in JAFROC figure of merit (difference -0.01, P=.36). In subgroup analysis, abdominal subspecialists demonstrated no evidence of change. Targeted training reduced search errors but not classification errors for the detection of hepatic metastases at contrast-enhanced abdominal CT. Improvements were not seen in all subgroups.

Newly Appearing Hepatic Lesion After Curative Surgery For Colorectal Cancer: Single-phase CT Findings Implying Metastasis.

In patients treated with curative surgery for colorectal cancer, the single-phase (portal phase) abdomen-pelvic computed tomography (CT) follow-up is routinely performed to detect any recurrent lesions. The objective of this study is to evaluate CT features implying metastasis in newly appearing hepatic lesions on single-phase CT after colorectal cancer surgery. Of 1,227 patients who underwent curative colorectal surgery between 2011 and 2014, 267 patients with new hepatic lesions on follow-up single-phase CT (metastasis, n=192; benign, n=75) were included. The CT features of the hepatic lesions were analyzed by two radiologists retrospectively, and clinical information, including carcinoembryonic antigen (CEA) level was also reviewed. The risk factors for hepatic metastasis were evaluated by multivariable logistic regression. In this study, independent CT features associated with metastasis were spherical shape (p < 0.001), circumscribed margin (p = 0.021), heterogeneous attenuation (p = 0.024) and bulging appearance (p = 0.007). Among the clinical factors, increased CEA level (p = 0.013), higher preoperative stage (p = 0.014) and lymphovascular invasion (p = 0.003) were associated with metastasis. However, on multivariable analysis, spherical shape was the only significant predictive factor for hepatic metastasis. The diagnostic performance of 'spherical shape' for detection of hepatic metastasis showed an accuracy of 84.6%, sensitivity of 83.9%, and specificity of 86.7%. Specific single-phase CT features could be useful in distinguishing hepatic metastasis from benign, resulting in continuing routine CT follow-up without liver magnetic resonance imaging (MRI) when metastasis is unlikely.

Is it possible to use low-dose deep learning reconstruction for the detection of liver metastases on CT routinely?

To compare the image quality and hepatic metastasis detection of low-dose deep learning image reconstruction (DLIR) with full-dose filtered back projection (FBP)/iterative reconstruction (IR). A contrast-detail phantom consisting of low-contrast objects was scanned at five CT dose index levels (10, 6, 3, 2, and 1 mGy). A total of 154 participants with 305 hepatic lesions who underwent abdominal CT were enrolled in a prospective non-inferiority trial with a three-arm design based on phantom results. Data sets with full dosage (13.6 mGy) and low dosages (9.5, 6.8, or 4.1 mGy) were acquired from two consecutive portal venous acquisitions, respectively. All images were reconstructed with FBP (reference), IR (control), and DLIR (test). Eleven readers evaluated phantom data sets for object detectability using a two-alternative forced-choice approach. Non-inferiority analyses were performed to interpret the differences in image quality and metastasis detection of low-dose DLIR relative to full-dose FBP/IR. The phantom experiment showed the dose reduction potential from DLIR was up to 57% based on the reference FBP dose index. Radiation decreases of 30% and 50% resulted in non-inferior image quality and hepatic metastasis detection with DLIR compared to full-dose FBP/IR. Radiation reduction of 70% by DLIR performed inferiorly in detecting small metastases (< 1 cm) compared to full-dose FBP (difference: -0.112; 95% confidence interval [CI]: -0.178 to 0.047) and full-dose IR (difference: -0.123; 95% CI: -0.182 to 0.053) (p < 0.001). DLIR enables a 50% dose reduction for detecting low-contrast hepatic metastases while maintaining comparable image quality to full-dose FBP and IR. • Non-inferiority study showed that deep learning image reconstruction (DLIR) can reduce the dose to oncological patients with low-contrast lesions without compromising the diagnostic information. • Radiation dose levels for DLIR can be reduced to 50% of full-dose FBP and IR for detecting low-contrast hepatic metastases, while maintaining comparable image quality. • The reduction of radiation by 70% by DLIR is clinically acceptable but insufficient for detecting small low-contrast hepatic metastases (< 1 cm).

A 25-reader performance study for hepatic metastasis detection: lessons from unsupervised learning.

There is substantial variability in the performance of radiologist readers. We hypothesized that certain readers may have idiosyncratic weaknesses towards certain types of lesions, and unsupervised learning techniques might identify these patterns. After IRB approval, 25 radiologist readers (9 abdominal subspecialists and 16 non-specialists or trainees) read 40 portal phase liver CT exams, marking all metastases and providing a confidence rating on a scale of 1 to 100. We formed a matrix of reader confidence ratings, with rows corresponding to readers, and columns corresponding to metastases, and each matrix entry providing the confidence rating that a reader gave to the metastasis, with zero confidence used for lesions that were not marked. A clustergram was used to permute the rows and columns of this matrix to group similar readers and metastases together. This clustergram was manually interpreted. We found a cluster of lesions with atypical presentation that were missed by several readers, including subspecialists, and a separate cluster of small, subtle lesions where subspecialists were more confident of their diagnosis than trainees. These and other observations from unsupervised learning could inform targeted training and education of future radiologists.

Comparison of Diagnostic Performance and Confidence between Contrast-Enhanced Computed Tomography Scan and Non-Contrast-Enhanced Computed Tomography Plus Abdomen Ultrasound for Hepatic Metastasis in Patients with Breast Cancer.

Background:The purpose of this study was to compare the performance between noncontrast-enhanced computed tomography (NECT) plus abdominal ultrasound (US) (NECT + US) with contrast-enhanced computed tomography (CECT) for the detection of hepatic metastasis in breast cancer patient with postsurgical follow-up.Methods:A total of 1470 patients without already diagnosed hepatic metastasis were included. All patients underwent US and multiphase CECT including the NECT. Independent reviewers analyzed images obtained in four settings, namely, abdominal US, NECT, NECT + US, and CECT and recorded liver metastases using a 5-grade scale of diagnostic confidence. Sensitivity, specificity (diagnostic performance), and area under the receiver operating characteristic curve (AUC, diagnostic confidence) were calculated. Interoperator agreement was calculated using the kappa test.Results:Reference standards revealed no metastases in 1108/1470 patients, and metastasis was detected in 362/1470 patients. Abdominal US (P < 0.01) and NECT (P = 0.01) significantly differed from CECT, but NECT + US did not significantly differ from CECT in terms of sensitivity (P = 0.09), specificity (P = 0.5), and AUC (P = 0.43). After an additional review of abdominal US, readers changed the diagnostic confidence scores of 106 metastatic lesions diagnosed using NECT. Interobserver agreements were good or very good in all four settings. Additional review of abdominal US with NECT allowed a change in the therapeutic plan of 108 patients.Conclusion:Abdominal US + NECT showed better diagnostic performance for the detection of hepatic metastases than did NECT alone; its diagnostic performance and confidence were similar to those of CECT.

Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study.

This study aimed to compare contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) with fundamental B-mode endoscopic ultrasonography (EUS) and contrast-enhanced computed tomography (CE-CT) for the diagnosis of left hepatic lobe metastases of pancreatic adenocarcinoma. In this single-center prospective study, CE-CT, EUS, and CH-EUS were performed to detect left hepatic lobe metastases in patients with pancreatic adenocarcinoma, and the detection rates were compared between EUS plus CH-EUS and the other two modalities. Subgroup comparisons of between-modality detection rate were performed in patients with only metastases of <10mm. The number of pancreatic adenocarcinoma patients whose clinical stage and treatment strategy were changed because of EUS plus CH-EUS findings was also assessed. Thirty-one patients were diagnosed with left hepatic lobe metastases. For overall detection of left hepatic lobe metastases, EUS plus CH-EUS had significantly higher accuracy (94.3%) than CE-CT (86.7%) and EUS alone (87.6%) (P=0.021 and P=0.020, respectively). For detection of left hepatic lobe metastases<10mm, EUS plus CH-EUS (93.3%) was significantly superior to CE-CT (84.4%) and EUS alone (85.6%) (P=0.021 and P=0.020, respectively). In five of the 11 patients in whom only CH-EUS allowed detection of hepatic metastases, the stage and/or treatment strategy of the pancreatic adenocarcinoma was changed after CH-EUS. This study demonstrated that EUS plus CH-EUS has advantages over CE-CT and EUS alone with regard to the accuracy of detecting left hepatic lobe metastases, particularly small hepatic metastases and accurate staging.

Accuracy of 18F-FDG PET/CT in monitoring therapeutic response and detection of loco-regional recurrence and metastatic deposits of colorectal cancer in comparison to CT

BackgroundThe study shows the role of PET/CT in monitoring response to therapy in colorectal cancer as well as detection of loco-regional recurrence and metastatic deposits hence guiding the clinician to the proper management strategy. Sixty patients (41male and 19 female) were included in our study. All patients are pathologically proven colorectal cancer. They had undergone 18F-FDG PET/CT for follow up post-therapeutic (operative, and/or chemotherapy and/or radiotherapy) follow up for metastatic or recurrent colorectal cancer during the period from September 2015 to August 2017.ResultsOur study demonstrated that FDG PET/CT is highly sensitive and specific in assessing local recurrence and distant metastasis in patient with pathologically proved colorectal cancer, with sensitivity 95.45%, specificity 97.3%, and accuracy 96.7% in detection of local recurrence; and sensitivity, specificity, and accuracy of 100% in detection of hepatic metastasis as well as in detection of nodal metastasis.ConclusionFDG PET/CT is an accurate modality in the treatment plan of cancer colon in monitoring therapeutic response as well as defining their local extent and distant metastatic disease thus provides valuable information that is very helpful in the clinical decision-making process.

03:09 PM Abstract No. 317 Prolonged survival after treatment of hepatic uveal melanoma metastases using immunoembolization

Control of uveal melanoma (UM) liver metastases is essential to prolonging overall survival (OS). At our institution, immunoembolization (IE) is considered a 1st line liver-directed therapy (LDT) for those with <50% hepatic tumor burden. A subset of patients experience a prolonged OS of ≥3 years with IE. The purpose of this study is to identify potential characteristics favoring prolonged OS. This is a single-institution IRB -exempt retrospective study of 174 patients (median age 60, range 26-87; 86 female) who initiated IE treatment for UM hepatic metastasis from 6/2005-12/2014. EMR, PACS, and an internal UM database were reviewed for primary tumor characteristics, genetics, and treatment modality; metastatic disease characteristics; IR treatment history; adjuvant therapies; and OS. Patients were divided into 2 groups; patients who survived ≥3 years (Group A; n=28; 19 female) and those who survived <3 years (Group B; n=146; 67 female) Kaplan-Meier, unpaired t-test and chi square test were used for data analysis. Median OS (n=174) was 16.8 months (range, 2.1-94.8). OS was 70.1% at 1 year, 32.8% at 2 years, 16.1% at 3 years, 10.9% at 4 years, 5.2% at 5 years, 3.4% at 6 years, and 1.7% at 7 years. Median OS for Group A was 52.4 months (range 38.1-94.8) and for Group B, 15.4 months (range 2.1-34.3). Significant differences (p<0.05) were found in several categories. Group A was less likely to undergo enucleation, more likely to be female, had a longer interval before detection of hepatic metastasis and a longer interval between onset of hepatic metastasis and 1st IE. Group A was also more likely to be treated with IE only, have a longer time interval before changing LDT, have treatment breaks, achieve partial response/stable disease following completion of first IE, and less likely to undergo chemoembolization as 2nd line LDT. Specific characteristics were identified that favor a prolonged OS for patients with UM hepatic metastases.

Detection of Colorectal Hepatic Metastases Is Superior at Standard Radiation Dose CT versus Reduced Dose CT.

Purpose To evaluate colorectal cancer hepatic metastasis detection and characterization between reduced radiation dose (RD) and standard dose (SD) contrast material-enhanced CT of the abdomen and to qualitatively compare between filtered back projection (FBP) and iterative reconstruction algorithms. Materials and Methods In this prospective study (from May 2017 through November 2017), 52 adults with biopsy-proven colorectal cancer and suspected hepatic metastases at baseline CT underwent two portal venous phase CT scans: SD and RD in the same breath hold. Three radiologists, blinded to examination details, performed detection and characterization of 2-15-mm lesions on the SD FBP and RD adaptive statistical iterative reconstruction (ASIR)-V 60% series images. Readers assessed overall image quality and lesions between SD FBP and seven different iterative reconstructions. Two nonblinded consensus reviewers established the reference standard using the picture archiving and communication system lesion marks of each reader, multiple comparison examinations, and clinical data. Results RD CT resulted in a mean dose reduction of 54% compared with SD. Of the 260 lesions (233 metastatic, 27 benign), 212 (82%; 95% confidence interval [CI]: 76%, 86%) were detected with RD CT, whereas 252 (97%; 95% CI: 94%, 99%) were detected with SD (P < .001); per-lesion sensitivity was 79% (95% CI: 74%, 84%) and 94% (95% CI: 90%, 96%) (P < .001), respectively. Mean qualitative scores ranked SD images as higher quality than RD series images, and ASIR-V ranked higher than ASIR and Veo 3.0. Conclusion CT evaluation of colorectal liver metastases is compromised with modest radiation dose reduction, and the use of iterative reconstructions could not maintain observer performance. © RSNA, 2018.

Role of Positron Emission Tomography/Computed Tomography in Evaluation of Hepatic Focal Lesions

AbstractBackground: Positron Emission Tomography/Computed Tomography (PET/CT) has emerged as an increasingly im-portant functional diagnostic tool of various primary or metastatic cancers. PET/CT provides unique information with combined anatomical localization and the metabolic activity of the lesion. In contrast to morphological imaging techniques the 18F-flurodeoxyglucose (FDG) PET evaluates tumor via-bility based on glucose metabolism. By far the most extensive use of PET/CT imaging to date has been in the diagnosis, staging, follow-up and monitoring of malignancies.Aim of Study: The aim of this study was to evaluate the efficiency of PET/CT in the detection and characterization of hepatic focal lesions.Patients and Methods: Twenty patients were referred with hepatic focal lesions based on previous imaging modalities or histopathological examination who underwent combined PET/CT. Detailed retrograde lesion based and patient based analyses were performed for 84 detected hepatic lesions in 20 patients.Results: PET/CT showed sensitivity of 92.42% and spe-cificity of 83.33% in detection of various hepatic focal lesions and higher sensitivity of 100% and specificity of 100% in detection of hepatic metastases from different primaries. Also, PET/CT showed sensitivity of 95.31% in detection of malignant lesions and sensitivity of 75% in detection of benign lesions. So, PET/CT was useful to differentiate malignant from benign lesions in the liver.Conclusion: FDG PET/CT proved to be highly sensitive and specific in the assessment of hepatic focal lesions and was able to differentiate between malignant and benign hepatic focal lesions and their metabolic nature which significantly affect further management.

Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma.

Hepatic metastasis is the most critical prognostic factor for colorectal cancer (CRC), and early detection of CRC liver metastasis can significantly improve cancer patient outcomes. In this study, we examined the levels of CPA4 in CRC samples, and assessed the potential of serum CPA4 as a biomarker for predicting CRC liver metastasis. CPA4 positivity was observed in 68.4% (130/190) colorectal cancer tissues, and significantly correlated with Depth of invasion, Lymph node metastasis, Distant metastasis and Stage. In addition, high CPA4 expression was associated with poor overall survival, and was an independent prognostic marker in patients with CRC. In CRC serum samples, serum CPA4 concentrations in CRC-M1(S) patients (3717.89 ± 375.98 pg/mL) were significantly increased as compared to in CRC-M1(H) patients (3692.12 ± 261.51 pg/mL), CRC patients without liver metastasis (2480.47 ± 507.90 pg/mL) or healthy controls (2183.7 ± 621.7 pg/mL) (P < 0.05). Furthermore, high CPA4 concentration was significantly correlated with Distant metastasis, Lymph node involvement, Stage and poor overall survival of the patients with CRC. Logistic regression analysis revealed that serum CPA4 level and Lymph node metastasis were the significant parameters for predicting CRC liver metastasis. In leave-one-out-cross-validation, these two markers resulted in sensitivity (90.0%) and specificity (93.8%) for hepatic metastasis detection. Moreover, this combination could correctly classify 49 cases of the 50 CRC patients with heterochronous liver metastasis in an independent test set. Therefore, our results suggest that CPA4 is closely associated with CRC liver metastasis, and serum CPA4 concentration combined with lymph node involvement may be used as accurate predictors of liver metastasis in colorectal cancer.

Pancreatic cancer and liver metastases: state of the art.

Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.

Value of integrated PET/CT in detection of hepatic metastatic deposits

PurposeThe goal of this study was to assess the value of combined PET/CT using 18F-FDG in detection and characterization of hepatic metastatic lesions compared to isolated PET and CT in various malignancies. Patients and methodsThe study included 82 patients divided into six groups of primary malignancies to whom PET/CT scans were done. Detailed retrograde lesion based and patient based analyses were performed for 441 detected hepatic lesions in 82 patients to detect metastasis on PET, CT and PET/CT. A final diagnosis of metastasis was confirmed by biopsy or by further clinical and radiologic work-up. ResultsRegarding lesion based analysis, the PET/CT showed 98% sensitivity, 100% specificity, 100% PPV, 84% NPV and 98% accuracy compared with 98%, 98%, 99.7%, 84% and 98%, respectively, for PET, and 95%, 81%, 98%, 63% and 94%, respectively, for CT. In patient-based analysis, PET/CT and PET showed 99% sensitivity, 100% specificity, 100% PPV, 90% NPV and 99% accuracy compared with 100%, 56%, 95%, 100% and 95%, respectively for CT. The combined PET/CT has significantly improved the low CT sensitivity as well as both CT and PET specificities. ConclusionPET/CT provides accurate detection of hepatic metastasis and their metabolic nature which significantly affect further management.

The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: A comparison with unenhanced and Gd-EOB-DTPA enhanced MRI

ObjectivesTo compare the role of DWI vs. gadoxetic-acid-disodium enhanced MRI in the detection of colorectal hepatic metastases. MethodsFifty-four patients with 115 hepatic metastases were included in this retrospective study, approved by the Ethical Board. All patients underwent intraoperative-ultrasound and surgical resection within two weeks after MRI. Images were grouped in 4 sets, which were analyzed by two radiologists in different sessions: unenhanced T1-T2w (set A), set A plus DWI (set B), set A plus gadoxetic-acid-disodium (set C), set A plus DWI plus gadoxetic-acid-disodium (set D). For each set, metastases presence/size/site was reported. Interobserver agreement and statistical significance were assessed by Cohen’s kappa and Mc-Nemar’s test, respectively. ResultsReaders’ agreement was always very good (k>0.80). Mean sensitivity values were 84.3/92.1/95.6/97.3% for set A/B/C/D, respectively. Mean specificity, positive predicted, negative predicted, and accuracy values strongly and progressively increased in the various set too: from 62.5% (set A) to 85.0% as for specificity, from 92.8% to 97.3% as for positive predicted value, from 41.0% to 85.1% as for negative predicted value, and from 81.1% to 95.5% as for accuracy.For each reader from set A to D, the number of false negatives progressively decreases. ConclusionsFor both readers, DWI improved all statistical parameters in the unenhanced examinations, as for nodules either smaller or greater than 1cm, while in the EOB-enhanced examinations DWI prevalently increased specificity/negative predictive value.

Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.

Early detection of liver metastasis is important for improving colorectal cancer (CRC) patient survival. Our previous studies showed haptoglobin was highly expressed in primary CRC tissues, especially in heterochronous metastatic cases. Here, we assessed the potential of serum haptoglobin (sHP) as a biomarker for early detection of CRC liver metastasis by evaluating the sHP in 475 CRC patients and 152 healthy volunteers. In the training set (250 cases), sHP level in CRC-M1 (1773.18 ± 690.25 ng/mL) were significantly increased as compared to in CRC-M0 (1544.37 ± 1497.65 ng/mL) or healthy (917.76 ± 571.59 ng/mL). And the high sHP level was correlated with poor survival. Logistic regression analysis revealed that sHP, serum carcinoembryonic antigen (sCEA) and serum carbohydrate antigen 19.9 (sCA19.9) level were the significant parameters for detecting liver metastasis. In leave-one-out-cross-validation, these three markers resulted in 89.1% sensitivity and 85.8% specificity for hepatic metastasis detection. In an independent test set (225 cases), receiver operating characteristic curve analysis of sHP in CRC liver metastasis showed an area under the curve of 0.735, with a sensitivity of 87.2% and a specificity of 59.9%. Combination of sHP, sCEA and sCA19.9 improved diagnostic accuracy to 0.880, with a sensitivity of 88.5% and a specificity of 87.8%. Silencing of HP by specific shRNA significantly inhibited the LOVO and SW620 cell invasion, and suppressed xenograft tumor invasive growth. In summary, these results demonstrate that sHP is associated with poor prognosis of CRC patients and that HP promotes colorectal cancer cell invasion. sHP combining with sCA19.9 and sCEA may be used as accurate predictors of CRC liver metastasis.

EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

Detection of hepatic metastases during EUS is an important component of tumor staging. To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses. Retrospective study, survey. Single, tertiary-care referral center. Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period. EUS-FNA of solid hepatic masses. Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy. A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria. An EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.

Intraindividual Comparison of Diagnostic Performance in Patients With Hepatic Metastasis of Full-Dose Standard and Half-Dose Iterative Reconstructions With Dual-Source Abdominal Computed Tomography

The objectives of the study were to evaluate the image quality and diagnostic performance of sinogram-affirmed iterative reconstruction (SAFIRE) for detecting hepatic metastasis and to estimate the potential radiation dose reduction at abdominal computed tomography (CT). Fifty-nine consecutive patients (mean age, 59.2 years; range, 42-81 years) who had hepatic metastasis and who underwent dual-source abdominal CT were enrolled in this study. The image noise of the liver was compared between full-dose filtered back projection images (FD-FBP) and simulated half-dose images, which used only single-source projection data, and reconstructed with different strengths of SAFIRE (HD-SAFIRE(1-5)) by 1-way analysis of variance with Bonferroni correction. The diagnostic performance for hepatic metastasis was compared by logistic regression with the weighted least squares method and noninferiority test between the FD-FBP images and the half-dose sinogram-affirmed iterative reconstruction (HD-SAFIRE) images. As the SAFIRE strength increased, image noise decreased (P < 0.001). The images of HD-SAFIRE(2) showed similar image noise for liver parenchyma (13.4 Hounsfield unit [HU]), signal-to-noise ratio for liver parenchyma (9.2), and lesion-to-liver contrast-to-noise ratio (4.5), compared with the FD-FBP images (12.6 HU, P = 0.668; 9.6, P > 0.999; and 4.5, P > 0.999, respectively). The diagnostic accuracy for hepatic metastasis with the HD-SAFIRE(2) images (87.5%) was not different from that of the FD-FBP images (87.5%, P > 0.999). The diagnostic performance of the HD-SAFIRE(2) images was also noninferior to that of the FD-FBP images (95% confidence interval lower limit difference [-9.16%] excluding the -10% clinical noninferiority limit). The mean (SD) volume CT dose index of FD-FBP was 11.26 (2.66) mGy, and the mean (SD) radiation dose equivalent associated with HD-SAFIRE was estimated to be 5.63 (1.33) mGy. By applying SAFIRE2, the radiation dose could be reduced by up to 50% compared with the standard-of-care abdominal CT protocol without increasing image noise and without deteriorating diagnostic performance for the detection of hepatic metastasis.

Preoperative evaluation of colorectal carcinoma by multislice computed tomography

Objective The purpose of this study was to assess the role of multislice computed tomography (MSCT) in preoperative evaluation of colorectal carcinoma (CRC) and to compare the imaging findings with surgical/pathological findings. Patients and methods MSCT scan was performed for 44 patients with pathological proven CRC. All these patients underwent spiral computed tomography with oral and intravenous contrast administration. Surgery was subsequently performed in all patients and surgical specimens were sent for detailed pathologic analysis. The MSCT assessment was then compared with the histopathological findings for sensitivity, specificity, and accuracy. Results MSCT had 60% sensitivity and 83% specificity for assessment of local spread of disease, 69% sensitivity and 76% specificity for the evaluation of lymph nodal metastases, and 89% sensitivity and 96% specificity for hepatic metastases. In all cases, the visualized tumor growth with wide zone of resection and regional nodal chains were surgically removed. It was, however, the distant metastases that made a difference to the type of curative or palliative surgery planned, and in this study spiral computed tomography had 92% accuracy for detection of hepatic metastases. Conclusion MSCT has a significant role in preoperative evaluation and subsequent management of CRC.